RT Journal Article
SR Electronic
T1 Feasibility of an App-Assisted and Home-Based Video Version of the Timed up and Go Test for Patients with Parkinson Disease: vTUG
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.30.24314647
DO 10.1101/2024.09.30.24314647
A1 Grobe-Einsler, Marcus
A1 Gerdes, Anna
A1 Feige, Tim
A1 Maas, Vivian
A1 Matthews, Clare
A1 García, Alejandro Mendoza
A1 Fages, Laia Comas
A1 Davies, Elin Haf
A1 Klockether, Thomas
A1 Falkenburger, Björn H.
YR 2024
UL http://medrxiv.org/content/early/2024/10/01/2024.09.30.24314647.abstract
AB Background Parkinson Disease (PD) is a progressive neurological disorder. Current therapeutic trials investigate treatments that can potentially modify the disease course. Testing their efficiency requires frequent and precise clinical outcome assessments (COA) of symptoms that remain problematic under symptomatic treatments, such as gait and balance. Home-based examinations may enhance patient compliance and, in addition, produce more reliable results by assessing patients more regularly in their familiar surroundings.Objective The objective of this study was to assess the feasibility of a digitized COA designed to video record the Timed up and Go (vTUG) test at home via a study-specific smartphone app for patients with PD.Method In this study, 28 patients were recruited and asked to perform at home each week a set of three consecutive vTUG tests over a period of 12 weeks using an app. The videos were subjected to a manual review to ascertain the durations of the individual vTUG phases, as well as to identify any errors or deviations in the setup that might have influenced the result. To evaluate the usability and user-friendliness of the vTUG and app, the System Usability Scale (SUS) and User Experience Questionnaire (UEQ) were administered to patients at the study end.Results Overall, 19 patients completed the 12-week study, 17 of which recorded 10 videos or more. A total of 706 vTUGs with complete timings were recorded. Random Forest Regression yielded “time to walk up” as the most important segment of the vTUG for predicting the total time. Variance of vTUG total time was significantly higher between weeks than it was between the three consecutive vTUGs at one time point [F(254,23) = 6.50, p < 0.001]. The correlation between vTUG total time and UPDRS III total score was weak (r = 0.24). Yet, correlation between vTUG and a derived gait subscore (UPDRS III items 9-13) was strong (r = .59). A linear mixed-effects model revealed a significant effect of patient-reported motion status on vTUG total time. Including additional variables such as UPDRS III gait subscore, different footwear, and chairs used, further improved the model fit.Conclusion Assessment of gait and balance by home-based vTUG is feasible. Factors influencing the read-out were identified and could be controlled for future use and longitudinal trials.Competing Interest StatementMGE, CM, AMG, LCF, EHD are affiliated with Aparito Ltd, a wholly owned subsidiary of Eli Lilly and Company.Funding StatementAparito Ltd, a wholly owned subsidiary of Eli Lilly and Company.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Technische University Dresden, Germany (BO-EK-149032021_3) and written informed consent was obtained from all patients before the participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.